CG Oncology upgraded to Buy from Neutral at Goldman Sachs
The Fly

CG Oncology upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst Corinne Johnson upgraded CG Oncology to Buy from Neutral with a $50 price target. Following the recent clinical data from BOND-003, the Phase 2 study of cretostimogene, presented at AUA, the firm says the data reinforced its positive view on the clinical outlook for cretostimogene in high-risk non-muscle invasive bladder cancer and it raised its view of the odds of success to 85% from 75% previously. The firm also sees a large commercial opportunity for cretostimogene in NMIBC and views the overall data package as “competitive” compared to approved and clinical-stage products.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App